These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35103198)

  • 21. A Retrospective Review of Four-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Bleedings.
    Hitchcock ZR; Smith SD; Le LT; Lees LR; Brandt MD
    J Pharm Pract; 2023 Apr; 36(2):221-226. PubMed ID: 34231410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
    Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
    Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Andexanet Alfa versus Four-Factor Prothrombin Complex Concentrate for the Reversal of Factor Xa (FXa) Inhibitor-Associated Intracranial Hemorrhage: A Systematic Review of Retrospective Studies.
    Ferreira LO; Oldemburg RAL; Leitão Filho JM; Cerveira RA; Vasconcelos VW; da Costa GE; Rodrigues RDR; Lopes DCF
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892788
    [No Abstract]   [Full Text] [Related]  

  • 24. A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding.
    Jaspers T; Shudofsky K; Huisman MV; Meijer K; Khorsand N
    Res Pract Thromb Haemost; 2021 May; 5(4):e12518. PubMed ID: 34084991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
    Chaudhary R; Singh A; Chaudhary R; Bashline M; Houghton DE; Rabinstein A; Adamski J; Arndt R; Ou NN; Rudis MI; Brown CS; Wieruszewski ED; Wanek M; Brinkman NJ; Linderbaum JA; Sorenson MA; Atkinson JL; Thompson KM; Aiyer AN; McBane RD
    JAMA Netw Open; 2022 Nov; 5(11):e2240145. PubMed ID: 36331504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
    Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
    J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.
    Brinkman HJM; Zuurveld M; Meijers JCM
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12775. PubMed ID: 35928523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery.
    Schmidt LE; Hinton MS; Martin ND
    J Pharm Pract; 2024 Feb; 37(1):74-79. PubMed ID: 36083782
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
    Tao J; Bukanova EN; Akhtar S
    J Intensive Care; 2018; 6():34. PubMed ID: 29942519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
    Coleman CI; Dobesh PP; Danese S; Ulloa J; Lovelace B
    Future Cardiol; 2021 Jan; 17(1):127-135. PubMed ID: 32618210
    [No Abstract]   [Full Text] [Related]  

  • 31. 4-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study.
    Estroff JM; Devlin J; Hoteit L; Hassoune A; Neal MD; Brown JB; Lu L; Kotch S; Hazelton JP; Christian AB; Yeates EO; Nahmias J; Jacobson LE; Williams J; Schuster KM; O'Connor R; Semon GR; Straughn AD; Cullinane D; Egodage T; Kincaid M; Rollins A; Amdur R; Sarani B
    J Trauma Acute Care Surg; 2024 Apr; ():. PubMed ID: 38685190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.
    Cohen AT; Lewis M; Connor A; Connolly SJ; Yue P; Curnutte J; Alikhan R; MacCallum P; Tan J; Green L
    J Am Coll Emerg Physicians Open; 2022 Apr; 3(2):e12655. PubMed ID: 35280921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
    Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
    Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
    Reynolds TR; Gilbert BW; Hall KM
    J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis.
    Orso D; Fonda F; Brussa A; Comisso I; Auci E; Sartori M; Bove T
    Crit Care; 2024 Jul; 28(1):221. PubMed ID: 38970010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review.
    Phillips A; Bradley C; Cash J; Sangiovanni R; Wingerson C
    Am J Health Syst Pharm; 2024 May; 81(11):e274-e282. PubMed ID: 38430127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
    Siepen BM; Polymeris A; Shoamanesh A; Connolly S; Steiner T; Poli S; Lemmens R; Goeldlin MB; Müller M; Branca M; Rauch J; Meinel T; Kaesmacher J; Z'Graggen W; Arnold M; Fischer U; Peters N; Engelter ST; Lyrer P; Seiffge D
    Int J Stroke; 2024 Jun; 19(5):506-514. PubMed ID: 38264861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
    Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
    Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
    Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
    J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.